Oculus Innovative Sciences, Inc. Announces Confidential Submission of Draft Registration Statement for Initial Public Offering to Securities and Exchange Commission by Its Subsidiary Ruthigen, Inc.

Published: May 28, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PETALUMA, Calif., May 28, 2013 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (the "Company") (Nasdaq:OCLS) a global healthcare company that designs, manufactures and markets prescription and non-prescription products in over 20 countries, today announced that Ruthigen, Inc., a wholly owned subsidiary of the company ("Ruthigen"), submitted a draft registration statement on a confidential basis to the U.S. Securities and Exchange Commission for a possible initial public offering of Ruthigen common stock. The number of shares to be offered and the price range for the offering have not yet been determined.

Help employers find you! Check out all the jobs and post your resume.

Back to news